Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...

The pharmaceutical company expects the expansion will create thousands of jobs.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.